Prognostic Factors for Chronic Spontaneous Urticaria: A 6-Month Prospective Observational Study by 諛뺤쨷�썝
© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org  115
INTRODUCTION
Chronic urticaria (CU) is a common skin disorder defined by 
recurrent wheals and itching for at least 6 weeks. Previous stud-
ies have revealed a point prevalence of 0.1%-1.0% in the gener-
al population.1,2 CU has major detrimental effects on the quality 
of life, with frequent sleep deprivation and psychiatric comor-
bidity.3 It also has a large impact on society in terms of direct 
and indirect health care costs, as well as reduced performance 
at work and in personal life.3 
Regarding the pharmacological treatment of CU, recent 
guidelines recommended a stepwise approach;4,5 however, pre-
vious results on the prognosis of CU are variable. CU has gener-
ally been recognized as a non-life-threatening and transiently 
symptomatic disease, with an average duration of 2 to 5 years.6 
Although few studies have evaluated the duration of CU, in 70% 
of patients, it persists for 1 year.7,8 In fact, more than 11% of CU 
patients have urticaria symptoms for more than 5 years.7 How-
ever, it is likely to occur longer in more severe cases.9 Factors 
predicting therapeutic response and disease severity are limit-
ed. Genetic factors related to mast cell activation and the over-
production of histamine and leukotriene have been suggested 
to contribute to disease development and clinical heterogene-
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ity.10 Angioedema, severe CU, and anti-thyroid antibodies have 
recently been identified as being associated with longer disease 
duration.9,11 In addition, since the correlation between a posi-
tive autologous serum skin test (ASST) and the presence of 
anti-FcɛRIα and anti-IgE antibodies was reported,12 investiga-
tors have attempted to demonstrate the utility of ASST as a bio-
marker for identifying a distinct subgroup of CU patients or for 
predicting treatment responses. However, to date, the associa-
tion between ASST positivity and clinical course of CU has been 
inconclusive.5,13 This study was designed to evaluate the prog-
nosis of a 6-month stepwise treatment and to determine pre-
dictors for control status in patients with CU.
MATERIALS AND METHODS
Subjects 
We performed a prospective observational study on 75 CSU 
patients (24 males and 51 females, age 19-69 years, mean age 
40.5 years) who were followed in the outpatient Allergy Clinic of 
3 university hospitals, including Ajou University Hospital, Sever-
ance Hospital, and Wonju Severance Christian Hospital in 
South Korea from November 2011 to March 2013. Inclusion cri-
teria were patients aged ≥19 years and having almost daily urti-
caria symptoms, such as wheals and itching, for at least 6 weeks. 
Patients with other chronic skin diseases and those with clinical 
evidence of urticarial vasculitis or inducible (physical stimuli or 
cholinergic or exercise) urticaria were excluded. Each patient 
submitted a written informed consent form at the time of enroll-
ment, and the Institutional Review Board approved the study. A 
stepwise treatment according to the recent guidelines4 was ap-
plied to all subjects. Our study protocol, including how to assess 
urticaria control and to apply stepwise treatment, was reviewed 
and accepted by all investigators before starting this study. In-
vestigators determined the first treatment step for each subject 
based on their medication history and current urticaria severity. 
Step I and II treatments correspond to up to 2 and 4 tablets of 
non-sedating antihistamines, respectively. The addition of leu-
kotriene receptor antagonist to 4 antihistamine tablets was the 
step III treatment. Immunosuppressive agents, including cyclo-
sporine and oral corticosteroids, were regarded as the step IV 
treatment. 
Assessment of urticaria activity scores and urticaria control 
CU disease activity was assessed using the urticaria activity 
score (UAS), which scores wheals according to quantity, distri-
bution range, mean diameter, and duration, in conjunction 
with pruritus according to the intensity within the last week for 
outpatient clinic visits, yielding a total score of 0-15.14 
Urticaria control state was classified into 4 categories accord-
ing to our previous report: remission, well-controlled, partly 
controlled, and uncontrolled.15 Remission was defined as the 
absence of urticaria symptoms for at least 4 weeks without any 
medication. Patients who had no wheals or itching when taking 
medication, but whose symptoms returned when they discon-
tinued their medication, were deemed to have well-controlled 
CU. Patients whose urticaria symptoms were reduced from the 
previous visit, but not completely controlled, were classified as 
partly controlled CU. Patients whose disease could not be con-
trolled by medication were deemed to have uncontrolled CU. 
The EAACI/GA2LEN/EDF/WAO guideline for the manage-
ment of urticaria recommends re-evaluation of the necessity 
for continued or alternative treatment every 3-6 months be-
cause of fluctuating disease activity of CU.16 Therefore, we as-
sessed urticaria control state and UAS at the initial visit and in 
the first, third, and sixth months after treatment, in total 4 times 
during the study period. However, patients were able to see in-
vestigators, whenever they wanted to discuss changes in their 
urticaria symptoms.
Autologous serum skin test 
Antihistamines were withdrawn at least 5 days before blood 
sampling. An intradermal autologous serum skin test (ASST) 
was performed according to the method described in the EAA-
CI/GA2LEN task force consensus report.17 A positive result was 
defined as a serum-induced wheal after 30 minutes with a di-
ameter of at least 1.5 mm greater than that induced by saline. 
Aspirin intolerance
Patients with aspirin intolerant chronic urticaria (AICU) was de-
fined as those who had a definite history of urticaria/angioedema 
development after the ingestion of aspirin and/or non-steroidal 
anti-inflammatory drugs (NSAIDs) and those who showed posi-
tive respones to the oral aspirin challenge test, as previously de-
scribed.18 The appearance of urticaria within 4 hours without any 
change in FEV1 was considered a positive result.
Assessment of atopy and measurement of total IgE, CRP, anti-
nuclear antibody (ANA), and anti-thyroid antibody 
Atopy was defined as a positive skin test response to at least 1 
common inhalant allergen, including pollens, animal dander, 
mold, and house dust mites (Allergopharma, Reinbek, Germany).
Total IgE levels were measured using the ImmunoCAP system 
(Thermo-Fisher, Uppsala, Sweden) according to the manufac-
turer’s instructions. ANA was detected using HEp-2 cells and an 
indirect fluorescent antibody technique (Fluoro HEPANA test; 
Medical & Biological Laboratories, Nagoya, Japan). Anti-thyro-
globulin and thyroid microsomal antibodies were detected by 
radioimmunoassay (BRAHMS Aktiengesellschaft, Hennigsdorf, 
Germany). Serum CRP (IBL-America, MN, USA) concentrations 
were measured by ELISA using commercially available reagents.
Statistical analysis
Data for continuous variables are shown as means±standard 
deviation (SD). Prevalence rates are shown as percentages. We 
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used the full analysis set (FAS), which includes all patients who 
received at least 1 dose of the assigned treatment, to describe 
the study populations included in the urticaria control analysis. 
Student’s t test and ANOVA were used for between-group com-
parisons of continuous variables. Categorical variables were 
compared using Pearson’s χ2 test. Mann-Whitney U and Fish-
er’s exact tests were applied for continuous and categorical 
variables in comparison between patients with ASST positivity 
and negativity, respectively. Logistic regression was used to ex-
amine the effects of various factors on remission or well-con-
trolled CU. The generalized estimating equation was used for 
examining the impact of the treatment step on urticaria control 
over the study period. The UAS and CU-QoL of the patients 
over the study period were examined by repeated-measures 
ANOVA according to the ASST results. We used the generalized 
estimating equation to evaluate the influence of baseline ASST 
results on urticaria control considering treatment step and du-
ration as covariates. A P value of <0.05 was considered to indi-
cate significance. All statistical analyses were performed using 
SPSS for Windows version 19.0 (SPSS, Chicago, IL, USA). 
RESULTS
Patients
Among a total of 80 patients, 59 patients completed this 
6-month prospective observational study. Of the 21 patients 
who were withdrawn from the study due to follow-up loss 
(n=14) and withdrawal of consent (n=2), with the exception of 
those who did not take medication during the study period 
(n=5), 16 were included in the statistical analysis. The baseline 
characteristics of 75 study patients whose urticaria control was 
evaluated at least once in the study period are shown in Table 1. 
The mean age of the patients was 40.5 years, 51 patients (68%) 
were female, and 21.9% of the 80 patients had aspirin intoler-
ance. The mean duration of their urticaria symptoms was 37.9 
months, and half of the patients had uncontrolled urticaria at 
the time of enrollment (Table 1). Of the 63 patients whose IgG 
autoantibodies, including anti-thyroid (thyroglobulin and mi-
crosomal) and anti-nuclear antibodies, were measured, 21 
(33.3%) exhibited a positive result indicating the presence of any 
of these 3 autoantibodies. There was no significant difference in 
urticaria duration (median, minimum-maximum) before the 
enrollment according to the presence of angioedema (13, 2-360 
vs 12, 2-120 months, P=0.445), anti-thyroid antibodies (13, 
2-240 vs 12, 2-360 months, P=0.840), and a positive ASST (6, 
2-108 vs 13, 2-360 months, P=0.122). In 25.4% of patients exhib-
iting positive ASST results, serum CRP (0.12±0.33 vs 0.60±0.99 
mg/mL, P=0.037) was significantly lower, while peripheral ba-
sophil levels (0.82±1.24 vs 0.28±0.57%, P=  0.020) were signifi-
cantly higher than in those with negative ASST results (Table 1). 
In addition, the frequency of serum autoantibodies tended to be 
increased in patients with positive ASST results (9/17, 52.9%) 
than in those with negative ASST results (10/38, 26.3%), al-
though statistical significance (P=0.071) was not reached. 
Table 1. Baseline characteristics according to the ASST results
Total
n=75 (%)
ASST
P value
Positive (n=17) Negative (n=50)
Age 40.5±12.3 38.2±11.8 41.1±12.4 0.489*
Gender (male) 24 (32.0) 5 (29.4) 16 (32.0) 1.000†
Urticaria duration (month) 12 (2-360) 6 (2-108) 13 (2-360) 0.122*
Angioedema 29 (38.7) 6 (35.3) 21 (42.0) 0.777†
UAS 9.9±3.6 9.5±4.1 10.1±3.6 0.722*
CU-QoL 58.0±20.3 57.3±18.6 57.9±21.6 0.863*
Atopy 37 (49.3) 11 (64.7) 23 (46.0) 0.262†
Aspirin intolerance 16 (21.9) 4 (25.0) 11 (22.0) 1.000†
Autoantibodies 21/63 (33.3) 9/17 (52.9) 10/38 (26.3) 0.071†
   Anti-thyroid 15/63 (33.3) 6 (35.3) 9/47 (19.1) 0.197†
   ANA 8 (10.7) 4 (23.5) (8.0) 0.187†
Total IgE (KU/L) 241.9±351.8 238.3±306.6 250.2±390.7 0.768*
ESR (mm/h) 14.8±11.3 11.9±6.3 16.0±12.9 0.461*
CRP (mg/L) 0.44±0.86 0.12±0.33 0.60±0.99 0.037*
Peripheral basophil (% of WBC) 0.41±0.79 0.82±1.24 0.28±0.57 0.020*
Controlled status at baseline
    Partly/Un-controlled 37/38 11/6 23/27 0.262†
P values were obtained by comparison between ASST positive and negative groups. 
*Mann-Whitney U test; †Fisher’s exact test. 
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Prognosis of chronic urticaria 
After 6 months of prospective observation, 2 (3.4%) and 21 
(35.6%) of the 59 patients were determined to have their urti-
caria in remission and well-controlled states, respectively (Fig. 
1). On the contrary, 16.9% of the patients remained at uncon-
trolled state even with the same stepwise treatment. The mean 
time to first well-controlled month was 4.4 months. There were 
no significant differences in demographics and clinical param-
eters among the 4 CU control statuses (Table 2). Two patients 
who achieved remission within 6 months had taken antihista-
mine monotherapy, while 60% of patients with uncontrolled 
CU had maintained at least step III treatment, including leukot-
riene antagonists and/or cyclosporine. In addition, 43.2% of the 
patients continuously advanced a treatment step during the 
study period. However, 29.7% of the patients maintained the 
treatment step at the beginning of the study, and 27.0% were 
able to step down over 6 months. 
The initial treatment steps of the patients were not different 
between groups I and II (Fig. 2) Approximately half of patients 
in either group did not have any maintenance treatment for CU 
at the enrollment, while 17.4% of group I and 16.7% of group II 
had been taking oral corticosteroids for more than 2 weeks. 
These results may reflect the lack of awareness about that CU is 
Table 2. Comparisons of clinical characteristics of CSU patients according to controlled status after 6-month stepwise treatment
Group I Group II
P value* P value†Remission 
(n=2)
Well 
controlled 
(n=21)
Remission or 
well-controlled 
(n=23)
Partly 
controlled 
(n=26)
Uncontrolled 
(n=10)
Partly 
controlled or 
uncontrolled 
(n=36)
Age (year) 38.5±17.7 42.9±12.8 42.5±12.8 40.5±12.2 39.1±10.3 40.1±11.5 0.839 0.470
Duration (month) 20.0±22.6 39.6±81.7 37.9±78.3 35.2±54.4 24.9±29.2 32.3±48.5 0.922 0.736
Onset age (year) 35.0±22.6 40.1±14.4 39.7±14.6 37.6±11.4 36.6±10.5 37.3±11.1 0.843 0.512
Female (%) 2 (100) 13 (61.9) 15 (65.2) 18 (69.2) 5 (50.0) 23 (63.9) 0.506 1.000
Atopy rate (%) 1 (50.0)   8 (38.1)   9 (39.1)   9 (34.6) 5 (50.0) 14 (38.9) 0.843 1.000
Angioedema (%) 2 (100)   8 (38.1) 10 (43.5)   7 (26.9) 5 (50.0) 12 (33.3) 0.161 0.582
ASA intolerance (%) 1 (50.0)   4 (20.0)   4 (17.4)   5 (29.2) 5 (50.0)   7 (19.4) 0.228 1.000
Baseline ASST 0 (0.0)   7 (46.7)   7 (41.2)   3 (12.0) 1 (11.1)   4 (11.8) 0.707 0.028
Baseline UAS   8.5±0.7   9.9±3.2   9.8±3.1   9.7±3.8   8.9±4.8   9.4±4.1 0.884 0.735
Baseline CU-QoL 75.0±0.0 60.6±15.6 61.9±15.5 58.3±23.8   57.3±21.2 58.0±22.8 0.539 0.663
Rescue steroid
   User (%) 0 (0.0) 4 (19.0) 4 (17.4) 6 (23.1) 7 (70.0) 13 (26.1) 0.015 0.150
   Frequency 0   0.8±1.9   0.7±1.8   1.2±2.6   4.4±3.3   2.1±3.1 0.002 0.034
   Dosage‡ 0   5.1±14.2   5.1±14.2 14.5±31.6 38.8±61.6 24.7±43.1 0.050 0.045
*Comparison among four urticaria controlled status and †comparison between groups I and II; ‡Equivalent dose (mg) of prednisolone.
ASA, aspirin; ASST, autologous serum skin test; UAS, urticaria activity score (0-15); CU-QoL, chronic urticaria-specific quality of life (0-100). 
Fig. 2. Treatment steps for controlling CU during the study period. Group I, pa-
tients with remission or well-controlled CU; Group II, patients with partly con-
trolled or uncontrolled CU.
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Fig. 1. Proportion of CU control status during the study period.
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a chronic disease whose aim of treatment is a complete symp-
tom control. None of the patients were taking cyclosporine at 
the time of enrollment. 
Comparison of clinical characteristics according to urticaria 
control
Urticaria control state was classified into 2 groups: group I (re-
mission and well-controlled) and group II (partly and uncon-
trolled). The baseline positive rate of ASST was significantly 
higher in group I compared to group II (41.2% vs 11.8%, P=  
0.028). Other parameters, including age, urticaria duration, 
gender, atopy rate, aspirin intolerance, baseline UAS, and CU-
QoL were not different between the 2 groups (Table 2). The fre-
quency (2.1±3.1 vs 0.7±1.8, P=0.034) and total dose (21.7±
14.2 vs 5.1±43.1 mg of prednisolone equivalent dose, P=0.045) 
of oral corticosteroid use for controlling urticaria exacerbation 
was significantly higher in group II compared to group I. How-
ever, the overall changes in treatment steps, as well as dosages 
of antihistamines, leukotriene antagonist, and cyclosporine, 
were not significantly different between the 2 groups. The gen-
eralized estimating equation revealed that changes in the pro-
portion of patients having the step IV treatment over the study 
period had no significant influence on the determination of the 
2 groups (Fig. 2, P=0.155).
Predictors for urticaria control
Table 3 summarizes the independent predictors of urticaria 
control in the study subjects. A significant association between 
ASST positivity and a better prognosis of CU was reproduced by 
a multivariate analysis after the adjustment for age, gender, 
baseline UAS and urticaria duration (Table 3). Changes from 
baseline in CU-QoL after the 6-month treatment were signifi-
cantly greater in group I compared to group II (29.9±17.3 vs 
14.1±23.0, P=0.007). The UAS changed significantly in group I 
from the baseline to the end of the study than in group II (-7.9±
3.8 vs -3.0±5.8, P=  0.001, Fig. 3). 
In addition, the mean scores of the UAS and CU-QoL for the 
Fig. 4. Mean UAS (A) and CU-QoL (B) scores over the study period according to the ASST results. Data are presented as mean±standard error. *P for interaction be-
tween time and ASST results at each visit from baseline <0.05. UAS, urticaria activity score; CU-QoL, chronic urticaria-specific quality of life; ASST, autologous se-
rum skin test.
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Table 3. Multivariate analysis for urticaria control (group I vs II) after 6-month 
stepwise treatment
P value OR 95% CI
Age (year) 0.386 1.025 0.969-1.085
Female gender 0.559 1.528 0.369-6.320
Urticaria duration (month) 0.387 1.004 0.995-1.085
Baseline UAS 0.558 1.053 0.887-1.249
Baseline ASST positivity 0.017 6.106 1.376-27.098
ASST, autologous serum skin test; UAS, urticarial activity score; OR, odds ratio; 
CI, confidence interval.
Fig. 3. Changes in UAS (A) and CU-QoL (B) according to control status. Data are 
presented as mean±standard error. UAS, urticaria activity score; CU-QoL, 
chronic urticaria-specific quality of life; group I, patients with remission or well-
controlled CU; group II, patients with partly controlled or uncontrolled CU.
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overall study period differed between patients with positive and 
negative ASST results (Fig. 4). The mean UAS of the patients de-
creased steeply after the first month of treatment and was main-
tained over time in both the positive and negative ASST groups. 
In patients with positive ASST results, the decrease in the mean 
UAS seemed to be remarkable, but was not significantly differ-
ent from those with negative ASST results. In contrast, the mean 
CU-QoL score in patients with positive ASST results was signifi-
cantly higher than in those with negative ASST results at the first 
month of treatment (80.0±20.3 vs 70.9±24.7, P=0.024). 
Fig. 5 shows the proportion of patients achieving well-con-
trolled CU according to both their treatment steps and baseline 
Fig. 5. The proportion of patients who achieved well-controlled CU stratified by their treatment steps and baseline ASST results over the study period. Grey bars 
show the proportion of patients according to their treatment steps at each visit. Black bars represent the proportion of patients who achieved well-controlled CU 
with respect to their treatment step at each visit.
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ASST results over the study period. Changes in treatment steps 
are not remarkable between ASST positive and ASST negative 
patients with positive and negative ASST results. Five of the 39 
patients with negative ASST results received the step IV treat-
ment in the 6th month. Among them, 1 (20%) patient achieved 
well-controlled CU. Two (50%) of the 4 ASST-positive patients 
receiving the step IV treatment at the last visit had well-con-
trolled status. The generalized estimating equation demon-
strated that a positive ASST (OR=2.648, 95% CI 1.256-5.583, 
P=0.011) was a significant determinant of well-controlled CU 
at the end of this study even after adjusting for the treatment 
step (OR=0.891, 95% CI 0.709-1.121, P=0.325) and treatment 
period (OR=1.232, 95% CI 1.086-1.397, P=0.001) as covariates.
 
DISCUSSION
In this study, we investigated remission and urticaria control 
status classified as well, partly, and uncontrolled, as well as fac-
tors related to the prognosis of CU using the standard treatment 
of 6 months. The CU remission rate within 6 months of step-
wise treatment based on recent guidelines4 was 3.4% in the 59 
patients. Regardless of their urticaria duration before enroll-
ment in this study, 39% of the patients achieved at least well-
controlled CU after 6 months. However, 61% of the patients suf-
fered from wheals and pruritus, without a significant difference 
in treatment pattern between the 2 groups. Considering that 
43.2% of the subjects continuously advanced in treatment steps 
during the study period, while 27.0% of patients were able to 
tolerate a step-down of treatment, 6 months of observation is 
insufficient to determine the exact prognosis of CU. The natural 
course of CU is unpredictable, and reported remission rates 
vary. In general, CU remission has been achieved in 11.5% to 
47.4% of patients at 1 year.8,9,11,19 However, to date, most studies 
investigating the prognosis of CU were retrospective,7,9,20 and 
they differ in terms of onset age, disease duration, and previous 
treatment step at the enrollment, as well as ethnicity.9 
This study suggests a potential use of ASST to predict the con-
trol status of CU over a 6-month period of stepwise treatment. 
The patients with negative ASST results at enrollment showed 
more severe CU in terms of higher CRP levels and more promi-
nent basopenia, which have previously been demonstrated to 
be associated with urticaria severity.21-23 Additionally, we previ-
ously demonstrated a significant association of negative ASST 
results with a higher prevalence of metabolic syndrome, which 
is a chronic, low-grade systemic inflammatory state that coex-
ists in severe CU patients.15 However, these results that patients 
with negative ASST results had more severe inflammatory con-
ditions at the beginning of the study suggest a possible limita-
tion in the assessment of the urticaria control under the same 
standard stepwise treatment for both ASST positive and nega-
tive groups. In addition, considering that some patients who 
had a longer disease duration, without statistical significance, 
were included in the ASST negative-group, we could not com-
pletely exclude a potential bias in subjects selection. However, 
multivariate regression analysis revealed that a positive ASST 
was a significant independent predictor of urticaria control 
over 6 months of stepwise treatment, whereas no significant 
difference was noted in urticaria duration and disease activity. 
The UAS was demonstrated to be a good parameter for pre-
dicting severe CU refractory to antihistamines in our previous 
studies.15,24 However, the baseline UAS in this study had no im-
pact on urticaria control, although changes in the UAS were sig-
nificantly different between groups I and II. The frequency and 
dosage of rescue steroid use during the study in CU patients 
were significantly different according to their control status. 
These results indicate that both UAS and CU-QoL can be useful 
parameters for monitoring the treatment response or control 
status in patients with CU. 
Angioedema, severe CU, and autoimmunity resulting in posi-
tive ASST and anti-thyroid antibodies or hypertension have re-
cently been identified as factors associated with a longer dis-
ease duration.9,11 However, a recent systematic review revealed 
no evidence to support the association between ASST positivity 
and a longer duration or disease activity in CU patients.13 Even 
though ASST is generally used and well established, variance in 
the positivity rate and clinical association of ASST has been is-
sued. The frequency of ASST positivity in CSU patients in this 
study (25.4%) is comparable with those of previous stud-
ies.11-13,17,25-27 There are considerable heterogeneous data on the 
prognostic role of ASST reactivity.13 Previous studies mainly in-
vestigated the association between ASST positivity and urticar-
ia duration/disease severity. Some studies showed increased 
disease activity or longer duration in ASST positive patients,11,28-31 
whereas no significant differences in severity,26,27,30,31 disease 
duration,26,27,29,30 and quality of life scores31 between the ASST-
positive and ASST-negative patients were noted in others. How-
ever, there has been no attempt to study on whether ASST reac-
tivity can predict urticaria control status and therapeutic re-
sponse in CSU patients. Staubach et al.31 reported that ASST-
positive CU patients require more antihistamines; however, 
their results were based on retrospective observation without 
further steps of treatment. In this study, we demonstrated that 
ASST positivity was a significant predictor of well-controlled CU 
during the 6-month stepwise treatment after adjusting for urti-
caria duration in a multivariate regression model considering 
the treatment step and duration as covariates in the generalized 
estimating equation. 
When we analyzed time from the onset of symptoms to en-
rollment in this study, the time appeared to be longer in pa-
tients having angioedema, anti-thyroid antibodies, and nega-
tive ASST results, albeit not significantly so. Additionally, the 
presence of angioedema or anti-thyroid autoantibodies had no 
impact on the control status of urticaria in previous studies. In 
contrast, our study demonstrated that the mean UAS and CU-
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QoL over the study period were more favorable in patients with 
positive ASST results as compared to those with negative ASST 
results. However, due to the limitations associated with the 
small number of patients, further prospective studies with a 
longer time frame using stepwise treatment are necessary to 
evaluate the clinical utility of ASST and to investigate other fac-
tors for predicting the prognosis of CU. 
Since only half of the ASST-positive sera induced histamine 
release from donor basophils, ASST results were suggested to 
indicate the presence of vasoactive factors other than IgG auto-
antibodies able to activate basophils.1,32,33 Serum factors present 
in CU patients are associated with ASST reactivity, and their 
role in the course of disease remains to be elucidated. We spec-
ulate that patients with positive ASST results have serum factors 
that enable the release of histamine and vasodilators that were 
controlled by antihistamines, whereas sera from ASST-negative 
patients may contain inflammatory mediators, such as CRP, 
that perpetuate inflammation rather than histamine-releasing 
factors. Therefore, the majority of ASST-positive patients whose 
urticaria symptoms are induced mainly by histamine are ex-
pected to achieve a well-controlled state within 6 months of 
treatment. Since exacerbating and triggering factors in CU pa-
tients are heterogeneous, it is unclear whether urticaria control 
state assessed at the end of the 6-month period would be main-
tained in the long term.  It is another limitation of our study not 
to evaluate whether functional histamine releasability of the 
sera from our study patients was different according to the 
ASST results. Therefore, further studies are needed to validate 
the association between ASST reactivity and the long-term 
prognosis of CU.
In conclusion, a 6-month stepwise treatment approach based 
on the recent guidelines induced a remission of 3.4% of patients 
from urticaria, and 35.6% of the 59 CU patients were able to 
achieve well-controlled status. Changes in the UAS and CU-
QoL from baseline levels are well correlated with CU control. A 
positive ASST has been identified as an independent predictor 
of well-controlled CU. However, future studies should investi-
gate which serum factors that induce ASST reactivity in CU pa-
tients are involved in the therapeutic response.
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